Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI (REC)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
02/19/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
30.68(c) 30.02(c) 29.5(c) 29.3(c) 29.06 Last
490 116 961 724 2 087 263 812 127 1 007 396 Volume
-1.45% -2.15% -1.73% -0.68% -0.82% Change
More quotes
Financials (€)
Sales 2018 1 375 M
EBIT 2018 437 M
Net income 2018 311 M
Debt 2018 234 M
Yield 2018 3,00%
Sales 2019 1 442 M
EBIT 2019 462 M
Net income 2019 333 M
Debt 2019 98,6 M
Yield 2019 3,15%
P/E ratio 2018 19,72
P/E ratio 2019 18,53
EV / Sales2018 4,66x
EV / Sales2019 4,35x
Capitalization 6 169 M
More Financials
Company
Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals.It operates through two segments: Pharmaceutical and Rare Diseases.The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and... 
Sector
Pharmaceuticals
Calendar
04/18Shareholder meeting
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
02/14RECORDATI : Regent Pacific says Fortacin officially launched in Europe
AQ
02/08RECORDATI : Preliminary 2017 results confirm continued growth of sales and profi..
GL
02/08RECORDATI : Preliminary 2017 results confirm continued growth of sales and profi..
GL
2017RECORDATI : Acquires transipeg®, transipeglib® and colopeg® for the french marke..
GL
2017RECORDATI : Acquires transipeg®, transipeglib® and colopeg® for the french marke..
GL
2017RECORDATI : Ex-dividend day for for interim dividend
FA
2017RECORDATI : Excellent results in the first nine months 2017. continued growth in..
PU
2017RECORDATI : Very good results in the first nine months 2017. continued growth in..
GL
2017RECORDATI : Very good results again in the first half 2017. continued growth in ..
PU
2017RECORDATI : Very good results in the first half 2017. continued growth in sales ..
GL
More news
Sector news : Pharmaceuticals - NEC
01:46pPUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
11:10aSHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
08:48aNOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on RECORDATI 
RECORDATI - 01/22
In an accumulation phase
BUY
RECORDATI SPA - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
02/08RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PRO.. 
01/20$RCDTF - FY2019 Earnings Estimate for Recordati #RCDTF Issued By Jefferies Gr.. 
01/20Jefferies Group Sets Recordati FY2019 Earnings Estimates at $2.23 EPS.  
01/18Jefferies Group Raises Recordati FY2017 Earnings Estimates to $1.83 EPS (Prev.. 
2017RECORDATI: ACQUIRES TRANSIPEG®, TRANSIPEGLIB® AND COLOPEG® FOR THE FRENCH MAR.. 
More tweets
Qtime:15
News from SeekingAlpha
02/08Recordati Industria Chimica e Farmaceutica reports FY results 
2017Recordati Industria Chimica e Farmaceutica reports 9M results 
2017Recordati Industria Chimica e Farmaceutica reports 1H results 
2017Strong Small Cap Performance Drives Second-Quarter Gains 
2017WALL STREET BREAKFAST : Major Shakeup At Ford? 
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | 4-Traders
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 37,0 €
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Andrea Recordati Vice Chairman & Chief Executive Officer
Alberto Recordati Chairman
Fritz Squindo Chief Financial Officer, Executive Director & MD
Mario Garraffo Independent Non-Executive Director
Marco Vitale Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI-20.94%7 589
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618